Glucoză Zentiva

Glucoză Zentiva is a sterile intravenous solution containing glucose monohydrate as the sole active ingredient. It is supplied as a solution for injection, manufactured for the EU market and available by prescription. The product provides a readily available source of carbohydrate for patients who require parenteral glucose, supporting cellular energy metabolism during hypoglycemia, fluid replacement, or parenteral nutrition and can be incorporated into standard intravenous therapy protocols.

Glucoză Zentiva is indicated for several clinical situations where rapid delivery of glucose is required.

- Treatment of documented hypoglycemia in patients who are unable to ingest oral carbohydrates, providing rapid rise in plasma glucose. - Provision of caloric support as part of total parenteral nutrition regimens, helping meet daily energy requirements when enteral feeding is not feasible. - Fluid and electrolyte replacement when combined with appropriate electrolyte solutions, assisting in the correction of dehydration and maintenance of osmolar balance. - Maintenance of blood glucose levels during surgical procedures or intensive care monitoring, reducing the risk of intra‑operative hypoglycemia. - Support for patients with metabolic disorders that limit endogenous glucose production, such as glycogen storage diseases or severe liver dysfunction.

When administered intravenously, Glucoză Zentiva may be associated with a range of observed effects, most of which are mild and transient.

Common: - Mild hyperglycemia that resolves without intervention. - Transient nausea or vomiting related to rapid glucose infusion. - Local irritation or mild pain at the injection site. - Slight increase in serum sodium due to osmotic shift. - Temporary feeling of warmth or flushing during infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis or electrolyte imbalance. - Allergic or anaphylactic reaction presenting with rash, itching, bronchospasm, or hypotension. - Hyperosmolar hyperglycemic state in patients with uncontrolled diabetes. - Volume overload in patients with heart failure leading to pulmonary edema. - Metabolic acidosis secondary to rapid glucose metabolism in susceptible individuals.

Before using Glucoză Zentiva, healthcare professionals should evaluate patient-specific factors and monitor for potential complications.

- Assess blood glucose levels prior to infusion and adjust rate to avoid excessive hyperglycemia. - Review cardiac and renal function, especially in patients at risk for fluid overload. - Use caution in individuals with known hypersensitivity to glucose solutions or any excipients. - Monitor electrolytes, particularly sodium and potassium, during and after administration. - Avoid rapid infusion rates exceeding recommended limits to reduce risk of osmotic shifts. - Consider alternative carbohydrate sources in patients with severe diabetes mellitus.

Glucoză Zentiva may interact with other intravenous therapies or medications that affect glucose metabolism, fluid balance, or electrolyte status.

Avoid: - Concurrent administration with high‑dose insulin infusions without appropriate glucose monitoring. - Co‑infusion of hypertonic saline solutions that could exacerbate hyperosmolarity. - Use together with other carbohydrate‑containing parenteral solutions unless total glucose load is calculated.

Use with caution: - Simultaneous use with diuretics, especially loop diuretics, may increase risk of electrolyte disturbances. - Combination with vasopressors may require careful volume management to avoid overload. - Patients receiving total parenteral nutrition should have the glucose contribution from Glucoză Zentiva accounted for in the overall caloric calculation.